ECSP12012312A - Tratamiento de enfermedades autoinmunes - Google Patents

Tratamiento de enfermedades autoinmunes

Info

Publication number
ECSP12012312A
ECSP12012312A ECSP12012312A ECSP12012312A EC SP12012312 A ECSP12012312 A EC SP12012312A EC SP12012312 A ECSP12012312 A EC SP12012312A EC SP12012312 A ECSP12012312 A EC SP12012312A
Authority
EC
Ecuador
Prior art keywords
alkyl
alkoxy
halogen
phenyl
trihalogenomethyl
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Peter Gergely
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012312(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12012312A publication Critical patent/ECSP12012312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ECSP12012312 2010-05-06 2012-11-27 Tratamiento de enfermedades autoinmunes ECSP12012312A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06

Publications (1)

Publication Number Publication Date
ECSP12012312A true ECSP12012312A (es) 2012-12-28

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012312 ECSP12012312A (es) 2010-05-06 2012-11-27 Tratamiento de enfermedades autoinmunes

Country Status (24)

Country Link
US (1) US20130172297A1 (enExample)
EP (1) EP2566470A1 (enExample)
JP (1) JP2013530937A (enExample)
KR (1) KR20130066630A (enExample)
CN (1) CN102869353A (enExample)
AU (1) AU2011249784B2 (enExample)
BR (1) BR112012028190A2 (enExample)
CA (1) CA2795394A1 (enExample)
CL (1) CL2012003091A1 (enExample)
CR (1) CR20120566A (enExample)
CU (1) CU20120154A7 (enExample)
EA (1) EA201201514A1 (enExample)
EC (1) ECSP12012312A (enExample)
IL (1) IL222690A0 (enExample)
MA (1) MA34285B1 (enExample)
MX (1) MX2012012926A (enExample)
NZ (1) NZ603999A (enExample)
PE (1) PE20130612A1 (enExample)
PH (1) PH12012502418A1 (enExample)
SG (1) SG185746A1 (enExample)
TN (1) TN2012000509A1 (enExample)
TW (1) TW201201814A (enExample)
WO (1) WO2011138393A1 (enExample)
ZA (1) ZA201207710B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
ES2351393T3 (es) * 2003-05-26 2011-02-03 Takeda Pharmaceutical Company Limited Sulfopirroles.
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
CN1918148B (zh) * 2004-02-11 2012-09-05 巴斯利尔药物股份公司 取代的苯并咪唑和它们诱导细胞凋亡的用途
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases

Also Published As

Publication number Publication date
EA201201514A1 (ru) 2013-05-30
AU2011249784A1 (en) 2012-12-20
TN2012000509A1 (en) 2014-04-01
CA2795394A1 (en) 2011-11-10
KR20130066630A (ko) 2013-06-20
TW201201814A (en) 2012-01-16
AU2011249784B2 (en) 2014-03-06
WO2011138393A1 (en) 2011-11-10
CN102869353A (zh) 2013-01-09
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
ZA201207710B (en) 2013-06-26
NZ603999A (en) 2014-06-27
PE20130612A1 (es) 2013-06-06
CU20120154A7 (es) 2013-03-27
MA34285B1 (fr) 2013-06-01
IL222690A0 (en) 2012-12-31
US20130172297A1 (en) 2013-07-04
CR20120566A (es) 2013-01-09
CL2012003091A1 (es) 2013-03-22
BR112012028190A2 (pt) 2016-08-02
MX2012012926A (es) 2012-12-17
JP2013530937A (ja) 2013-08-01
EP2566470A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
ECSP14028506A (es) Nucleósidos de espirooxetano de uracilo
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
CR10614A (es) Derivados heterociclicos fusionados y metodos de uso
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CR20140007A (es) N-(6-((2r, 3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
CL2010000959S1 (es) Aristas de un envase para cigarrillos que consisten en los lados menores de las caras superior e inferior de un cuerpo en forma de paralelepipedo recto vertical de cara superior perpendicular a las caras frontal y posterior, en tanto la cara inferior es inclinada descendente desde la cara superior hacia la cara frontal.
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
UY29503A1 (es) Derivados de amida sustituida y metodos de uso
ECSP10010623A (es) Compuestos triazina como inhibidores mtor y quinasa pi3
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
AR072085A1 (es) Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas
PE20121523A1 (es) Metodo de tratamiento
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
ECSP12012312A (es) Tratamiento de enfermedades autoinmunes
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
ECSP10010578A (es) Composicion farmaceutica 271
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112012028248A2 (pt) derivados de sulfeto de diarila, seu uso, e kit